# Everolimus as maintenance therapy in advanced neuroendocrine neoplasms: results from the MAVERIC phase II trial

## TL;DR

The MAVERIC trial found that everolimus, as maintenance therapy, significantly improved progression-free survival in patients with advanced neuroendocrine tumors after chemotherapy.

## Contribution

The study provides new evidence for the effectiveness of everolimus in metastatic neuroendocrine neoplasms with specific Ki-67 indices.

## Key findings

- Everolimus treatment resulted in a median progression-free survival of 11.8 months compared to 1.8 months in the control group.
- Toxicity was consistent with the known safety profile of everolimus, with common adverse events including mucositis and dyslipidemia.
- The treatment was particularly effective in GEP-NEN patients, showing a median progression-free survival of 19.9 months.

## Abstract

Neuroendocrine neoplasms (NEN) are a heterogeneous disease and chemotherapy (CT) represents the standard first-line treatment for those with a Ki-67 index >20%.

MAVERIC is a randomized, multicenter, non-comparative phase II study including patients with metastatic gastroenteropancreatic (GEP-NEN) or large-cell neuroendocrine carcinoma (LCNEC) (Ki-67 20%-55%) according to the 2010 WHO grading system and at least stable disease after first-line CT. Patients were randomized (2:1) to everolimus 10 mg/day or observation until progression or treatment intolerance. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS) and safety.

Between November 2015 and June 2022, 30 patients were enrolled across 5 Italian centers, with 20 assigned to everolimus and 10 to observation. The analysis included 29 patients (52% GEP-NEN, 48% LCNEC). Median (m)PFS was 11.8 months in the everolimus arm and 1.8 months in the control arm. MOS was similar between arms (38.3 and 38.2 months). The subgroup of 11 patients with GEP-neuroendocrine tumor (NET) grade 3 treated with everolimus showed an mPFS of 19.9 months and mOS of 48.1 months. Most common adverse events (AEs) were mucositis (80%), dyslipidemia (55%), fatigue (45%), pneumonitis (40%), and peripheral edema (35%). Grade 3 AEs occurred in 70% of patients; no grade 4 AEs were observed.

The MAVERIC trial demonstrated encouraging clinical benefit of everolimus in metastatic GEP-NEN and LCNEC (Ki-67 20%-55%) following first-line CT. Toxicity was consistent with the known safety profile of everolimus. This strategy was particularly effective in GEP-NEN patients and warrants further investigation. ClinicalTrials.gov identifier: NCT02687958 (https://clinicaltrials.gov/study/NCT02687958).